Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06937190

Pre-Sleep Creatine Enhances Anaerobic Power in Recreationally Active Females

This study is a randomized, double-blind, placebo-controlled trial designed to examine the effects of pre-sleep creatine monohydrate supplementation on anaerobic performance and muscle damage markers in recreationally active females. Participants will be randomly assigned to receive either 5 grams of creatine monohydrate or a placebo 30 minutes before sleep for seven consecutive days. Anaerobic performance will be assessed using the Wingate Anaerobic Test, evaluating peak and average power output and fatigue index. Blood samples will be collected before and after the supplementation period to analyze markers of muscle damage, including creatine kinase and lactate dehydrogenase. This study aims to provide insight into the efficacy of short-term, time-specific creatine supplementation for enhancing performance and recovery.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Anaerobic Performance Creatine Supplementation Exercise Recovery Female Athletes Muscle Fatigue Recreational Physical Activity Sports Nutrition

Age range

18 year–25 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Islamic Azad University, Shabestar Branch

Shabestar, East Azerbaijan Province, 5381637183, Iran

Location status: Recruiting

Location contact

Morteza Jourkesh, PhD

CONTACT

[email protected]

+98 938 278 4093

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Female, aged 18 to 25 years

Recreationally active (engaging in structured resistance training 3-4 times per week for the past 6 months)

Regular menstrual cycles (used for scheduling purposes)

Able and willing to provide informed consent

Agreement to maintain normal diet and training routines throughout the study

Exclusion criteria

History of musculoskeletal injury affecting lower or upper limbs within the past 6 months

Known allergy or intolerance to creatine or maltodextrin

Use of performance-enhancing substances or supplements within the last 30 days

Use of recovery modalities such as massage, cryotherapy, or compression garments during the study period

Current use of anti-inflammatory medication

Pregnancy or breastfeeding

Inability to comply with study protocol or scheduled assessments

Treatment and study plan

Creatine Monohydrate

Dietary Supplement

Participants will receive 5 grams of creatine monohydrate powder dissolved in water, flavored with a sugar-free agent, 30 minutes before sleep each night for 7 days.

Placebo (Maltodextrin)

Dietary Supplement

Visually identical placebo (maltodextrin powder, 5 g/day), flavored with a sugar-free agent, dissolved in water and consumed 30 minutes before sleep for 7 consecutive days.

Primary outcomes

  1. Average Power Output (Watts) - 30-Second Wingate Test

    Time frame: Baseline and post-intervention (Day 0 and Day 7)

    Average anaerobic power output will be calculated across the 30-second Wingate cycling test.

Secondary outcomes

  1. Peak Power Output (Watts) - Wingate Test

    Time frame: Baseline and post-intervention (Day 0 and Day 7)

    Peak power output during the initial 5 seconds of the 30-second Wingate cycling test.

  2. Fatigue Index (%) - Wingate Test

    Time frame: Baseline and post-intervention (Day 0 and Day 7)

    Calculated as the percent drop in power from peak to minimum power output during the 30-second Wingate test, indicating fatigue rate.

  3. Serum Creatine Kinase (CK) Activity

    Time frame: Baseline and 24 hours post Wingate Test (Day 0 and Day 8)

    Serum creatine kinase activity will be measured as a marker of muscle damage using a spectrophotometric assay.

  4. Serum Lactate Dehydrogenase (LDH) Activity

    Time frame: Baseline and 24 hours post Wingate Test (Day 0 and Day 8)

    Serum lactate dehydrogenase activity will be measured as an indicator of cell membrane permeability and muscle damage using spectrophotometry.

Study contacts

Contact information is provided by the study sponsor or research team.

Caglar Soylu, phD

CONTACT

[email protected]

+90 5078593595

Morteza Jourkesh, PhD

CONTACT

[email protected]

+98 938 278 4093

Sponsors and collaborators

Lead sponsor

Ankara Yildirim Beyazıt University

Other

Registry information

Acronym: SleepCrM

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Apr 22, 2025
Registry last updated
Apr 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.